Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Back to The Tape

Zacks Investment Research

19 Jun 2026, 09:25 UTC · 3h ago

Outset Medical (OM) Surges 25.6%: Is This an Indication of Further Gains?

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

ShareX LinkedIn

Outset Medical (OM) Surges 25.6%: Is This an Indication of Further Gains?

What the story claims

2 claims · each scored for market impact

What matters in this story

1
Outset Medical entered into an agreement with HCA Management Services to refresh its fleet of Tablo Hemodialysis Systems from 2026 to 2028 for approximately $40 million. — This provides a guaranteed future revenue stream and validates the product's adoption by a major healthcare provider.
+0.60
2
Outset Medical is expected to report a quarterly loss of $0.63 per share and a revenue decline of 8.3% year-over-year in its upcoming report. — Weakening top-line growth and widening losses create fundamental headwinds despite the recent contract win.
-0.40

Which stocks this story touches

How each ticker is affected

OM+0.80
Shares soared 25.6% following a $40 million contract amendment with HCA.

6 related stories

Zacks Investment Research
18h ago
Penumbra Receives CE Nod for THUNDERBOLT: Stock to Gain?
- healthcare
- medical devices
Read

Outset Medical (OM) Surges… — OM +0.80 | NewsImpactScreener

Outset Medical (OM) Surges 25.6%: Is This an Indication of Further Gains?

What matters in this story

How each ticker is affected

Penumbra Receives CE Nod for THUNDERBOLT: Stock to Gain?

Outset Medical (OM) Surges 25.6%: Is This an Indication of Further Gains?

What matters in this story

How each ticker is affected

Penumbra Receives CE Nod for THUNDERBOLT: Stock to Gain?

Connected tickers

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

The U.S. has launched a trade investigation into a German plan to cut spending on pharmaceuticals, a move that could result in fresh tariffs

Replicate Bioscience Awarded Grant to Advance srRNA Vaccine Candidates for Tuberculosis

WGS EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026

Press Release: Sanofi's Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma

Biodesix (BDSX) Surges 10.5%: Is This an Indication of Further Gains?

Outset Medical (OM) Surges 25.6%: Is This an Indication of Further Gains?

What matters in this story

How each ticker is affected

Next reads from the same story arc

Penumbra Receives CE Nod for THUNDERBOLT: Stock to Gain?

Outset Medical (OM) Surges 25.6%: Is This an Indication of Further Gains?

What matters in this story

How each ticker is affected

Next reads from the same story arc

Penumbra Receives CE Nod for THUNDERBOLT: Stock to Gain?

Connected tickers

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

The U.S. has launched a trade investigation into a German plan to cut spending on pharmaceuticals, a move that could result in fresh tariffs

Replicate Bioscience Awarded Grant to Advance srRNA Vaccine Candidates for Tuberculosis

WGS EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026

Press Release: Sanofi's Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma

Biodesix (BDSX) Surges 10.5%: Is This an Indication of Further Gains?